Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 31

Sort by

Sort Order Select

Journal Articles

Investigational Cell Therapy Beyond Oncology: Education, Communication, and Lessons Learned from Utilizing a Centralized Oncology Based Cell Therapy Program

Neil Bailey, Tenzin Tsomo, Jordan Briggs, Tori Braun, Krystle Pagarigan, Morgan Hanson, Phuong Nam Doan, Kory Barrow, Wezi Longwe, Rachael Crickman, Evonne Lackey, Swathi Namburi, Matthew Schwede, Krish Patel

Blood (2024) 144 (Supplement 1): 7956.

https://doi.org/10.1182/blood-2024-208076

Published: 2024

Journal Articles

Real-World Outcomes of CD19CAR T Cell Therapy in Adult Patients with Relapsed Refractory Transformed Indolent Lymphoma

Blood (2024) 144 (Supplement 1): 524.

https://doi.org/10.1182/blood-2024-198749

Published: 2024

Journal Articles

TP53 -Altered Aggressive Large B-Cell Lymphoma (LBCL) Outcomes By Treatment Modality: A Multicenter Cohort from 14 U.S. Centers

Blood (2024) 144 (Supplement 1): 6451.

https://doi.org/10.1182/blood-2024-194844

Published: 2024

Journal Articles

Outcomes of Therapies Following Discontinuation of Non-Covalent Bruton's Tyrosine Kinase Inhibitors for Patients with Chronic Lymphocytic Leukemia and Richter Transformation: Results from an International, Multicenter Study

Blood (2024) 144 (Supplement 1): 1870.

https://doi.org/10.1182/blood-2024-194748

Published: 2024

Journal Articles

Updated Response and Safety for Acalabrutinib Plus RICE Followed By Autologous Hematopoietic Cell Transplantation and/or Acalabrutinib Maintenance Therapy for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Neil Bailey, Tori Braun, Megumi Bailey, Tenzin Tsomo, Jennie Szeto, Swathi Namburi, Joanna Fesler, Sonia Glennie, Vanessa Dunleavy, Julia Carolyn Bokma Parker, Gayle Funk, Heidi Hohmann, Chiachun Lu, Jordan Briggs, Krish Patel

Blood (2024) 144 (Supplement 1): 3111.

https://doi.org/10.1182/blood-2024-209252

Published: 2024

Journal Articles

Molecular and Clinical Determinants of CAR-T Therapy Response in DLBCL

Devang Thakkar, Brian T. Hill, Rachel Kositsky, Shari Tian, Leonardo Biral, Veronica Russell, Tushar Dave, Cassandra L. Love, Caroline Roth, Matthew Stuart McKinney, Ahmed Galal, Jadee Neff, Agrima Mian, Ellen Kendall, Sarah L. Ondrejka, Matthew Chiaramonte, Govind Bhagat, Kenneth N. Ofori, Ran Reshef, Alexandra E. Kovach, Tarsheen Sethi, Emily F. Mason, Shakthi Bhaskar, Olalekan O. Oluwole, Chad McCall, Christopher Pallas, Nilanjan Ghosh, Robert Ferdman, George Chen, Francisco Hernandez-Ilizaliturri, Joanna Zurko, Ashley Cunningham, Nirav C Shah, Boyu Hu, Deborah M. Stephens, Monalisa Ghosh, Neil Bailey, Krish Patel, John M. Pagel, Kavya Kannamma Kannan, Eric D. Hsi, Rakhee Vaidya, Andrew Ip, Andre Goy, Swetha Kambhampati, Robert Ohgami, Charalambos Andreadis, Christian A Gordillo, Brianna Just, Jonathon B Cohen, Arielle Baim, Julie Barbello, Erika Cavallone, Veronika Bachanova, Maureen Laschen, Andinet Teferra, Frederique Lorcy, Sylvain Lamure, Guillaume Cartron, Valerie Dardalhon, Kikkeri N Naresh, Magdalena Czader, Anupama Reddy, Elizabeth Thacker, Clayton Parker, Lanie Happ, Sandeep Dave

Blood (2024) 144 (Supplement 1): 3409.

https://doi.org/10.1182/blood-2024-199758

Published: 2024

Journal Articles

Treatment Patterns and Outcomes for Patients with Classic Hodgkin Lymphoma (cHL) and Cardiomyopathy with Low Ejection Fraction (EF): Real-World Evidence (RWE) from 16 US Academic Centers

Blood (2023) 142 (Supplement 1): 382.

https://doi.org/10.1182/blood-2023-182389

Published: 2023

Journal Articles

Real-World Outcomes of CD19CAR T Cell Therapy in Adult Patients with Relapsed Refractory Transformed Indolent Lymphoma

Swetha Kambhampati, Reid W. Merryman, Yan Wang, Evandro Bezerra, Timothy Voorhees, Ayo S Falade, Madhav R Seshadri, Megumi Bailey, Neil Bailey, Krish Patel, Charalambos Andreadis, Adam S Kittai, Caron A Jacobson, Joycelynne Michelle Palmer, Annette Brown, Alex F. Herrera, L. Elizabeth Budde

Blood (2023) 142 (Supplement 1): 3511.

https://doi.org/10.1182/blood-2023-182467

Published: 2023

Journal Articles

Initial Efficacy and Safety of Acalabrutinib Plus RICE in Transplant Eligible Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Blood (2022) 140 (Supplement 1): 3765–3766.

https://doi.org/10.1182/blood-2022-164823

Published: 2022

Journal Articles

Outcomes of Therapies and Resistance Mutations Following Non-Covalent Bruton's Tyrosine Kinase Inhibitor Treatment for Patients with Chronic Lymphocytic Leukemia and Richter Transformation

Blood (2022) 140 (Supplement 1): 9885–9888.

https://doi.org/10.1182/blood-2022-159133

Published: 2022

Journal Articles

Impact of a Validated Composite Comorbidity Score on Outcomes in Patients Treated with CAR T-Cell Therapy for Diffuse Large B Cell Lymphoma (DLBCL): A Multicenter Real-World Evidence (RWE) Study

Blood (2022) 140 (Supplement 1): 2048–2050.

https://doi.org/10.1182/blood-2022-169872

Published: 2022

Journal Articles

Initial Safety Results from a Phase II Study of Acalabrutinib Plus RICE Followed By Autologous Hematopoietic Cell Transplantation and/or Acalabrutinib Maintenance Therapy for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Neil Bailey, Tenzin Tsomo, Tori Braun, Jennie Szeto, William I. Bensinger, Daniel Egan, Raya Mawad, Livia Hegerova, Gayle Funk, Joanna Fesler, Sonia Glennie, Judson Hall, Vanessa Dunleavy, Heidi Hohmann, Jordan Briggs, Joshua Mark, Megumi Bailey, John M. Pagel, Krish Patel

Blood (2021) 138 (Supplement 1): 4554.

https://doi.org/10.1182/blood-2021-148505

Published: 2021

Journal Articles

Impact of Comorbidities on Outcomes and Toxicity in Patients Treated with CAR T-Cell Therapy for Diffuse Large B Cell Lymphoma (DLBCL): A Multicenter Rwe Study

Blood (2021) 138 (Supplement 1): 529.

https://doi.org/10.1182/blood-2021-149735

Published: 2021

Journal Articles

Addressing a New Challenge in Chronic Lymphocytic Leukemia: Outcomes of Therapies after Exposure to Both a Covalent Bruton's Tyrosine Kinase Inhibitor and Venetoclax

Blood (2021) 138 (Supplement 1): 2628.

https://doi.org/10.1182/blood-2021-150751

Published: 2021

Journal Articles

Outcomes of Chronic Lymphocytic Leukemia and Richter Transformation Following Discontinuation of Non-Covalent Bruton's Tyrosine Kinase Inhibitors

Meghan C. Thompson, Catherine C. Coombs, Lindsey E. Roeker, John M. Pagel, Jeffrey L. Jensen, Kristen E. Battiato, Yehudit Fox, Kendall Meyer, Neil Bailey, Joanna M Rhodes, Paola Ghione, Bita Fakhri, Toby A. Eyre, Anthony R. Mato

Blood (2021) 138 (Supplement 1): 2629.

https://doi.org/10.1182/blood-2021-148592

Published: 2021

Journal Articles

Impact of Molecular Features of Diffuse Large B-Cell Lymphoma on Treatment Outcomes with Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy

Blood (2021) 138 (Supplement 1): 165.

https://doi.org/10.1182/blood-2021-145764

Published: 2021

Journal Articles

Awareness, Knowledge, and Preferences of United States (US) Patients with Chronic Lymphocytic Leukemia (CLL) and Their Caregivers Related to Finite Duration (FD) Therapy and Minimal (Measurable) Residual Disease (MRD)

Dr. Brian Koffman, Chris Stewart, Liza Avruch, Neil Bailey, Robyn Brumble, John C. Byrd, Alexey V. Danilov, Matthew S. Davids, Richard Furman, Nitin Jain, Neil E. Kay, Nicole Lamanna, Anthony R. Mato, Alan Skarbnik, Chaitra S. Ujjani, John M. Pagel

Blood (2021) 138 (Supplement 1): 1927.

https://doi.org/10.1182/blood-2021-145046

Published: 2021

Journal Articles

Real World Observational Study Using Clonoseq® Next Generation Sequencing in Hematologic Malignancies: The 'Watch' Registry

Krish Patel, MD, Neil Bailey, MSc, Cristina J. Gasparetto, MD, Tomer Mark, MD MSc, Bijal Shah, MD, Jakub Svoboda, MD, Michael A. Thompson, MD PhD, Heidi Simmons, PhD, Mark Schliekelman, PhD, Allison P. Jacob, Lance Baldo, MD, John M. Pagel, MDPhD

Blood (2020) 136 (Supplement 1): 37.

https://doi.org/10.1182/blood-2020-141440

Published: 2020

Journal Articles

A Phase 2, Open-Label, Multicenter Study of Tazemetostat in Combination with Rituximab for the Treatment of Relapsed or Refractory Follicular Lymphoma

Krish Patel, MD, Neil Bailey, MSc, John M. Pagel, MD PhD

Blood (2020) 136 (Supplement 1): 4.

https://doi.org/10.1182/blood-2020-136653

Published: 2020

Journal Articles

Acalabrutinib Plus RICE Followed By Autologous Hematopoietic Cell Transplantation and/or Acalabrutinib Maintenance Therapy for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Neil Bailey, MSc, Tenzin Tsomo, BS, Jennie Szeto, BA, William I Bensinger, MD, Daniel Egan, MD, Livia Hegerova, MD, Raya Mawad, MD, Ami Batchelder, PA, Joanna Fesler, ARNP, Heather Holdread, MS,NP, Sonia Glennie, ARNP, Judson Hall, ARNP, Joey Ferry, ARNP, Megumi Bailey, MSc, David Kane, RN, John M. Pagel, MDPhD, Krish Patel, MD

Blood (2020) 136 (Supplement 1): 34.

https://doi.org/10.1182/blood-2020-141074

Published: 2020

NARROW

Investigational Cell Therapy Beyond Oncology: Education, Communication, and Lessons Learned from Utilizing a Centralized Oncology Based Cell Therapy Program

Real-World Outcomes of CD19CAR T Cell Therapy in Adult Patients with Relapsed Refractory Transformed Indolent Lymphoma

TP53 -Altered Aggressive Large B-Cell Lymphoma (LBCL) Outcomes By Treatment Modality: A Multicenter Cohort from 14 U.S. Centers

Outcomes of Therapies Following Discontinuation of Non-Covalent Bruton's Tyrosine Kinase Inhibitors for Patients with Chronic Lymphocytic Leukemia and Richter Transformation: Results from an International, Multicenter Study

Updated Response and Safety for Acalabrutinib Plus RICE Followed By Autologous Hematopoietic Cell Transplantation and/or Acalabrutinib Maintenance Therapy for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Molecular and Clinical Determinants of CAR-T Therapy Response in DLBCL

Treatment Patterns and Outcomes for Patients with Classic Hodgkin Lymphoma (cHL) and Cardiomyopathy with Low Ejection Fraction (EF): Real-World Evidence (RWE) from 16 US Academic Centers

Real-World Outcomes of CD19CAR T Cell Therapy in Adult Patients with Relapsed Refractory Transformed Indolent Lymphoma

Initial Efficacy and Safety of Acalabrutinib Plus RICE in Transplant Eligible Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Outcomes of Therapies and Resistance Mutations Following Non-Covalent Bruton's Tyrosine Kinase Inhibitor Treatment for Patients with Chronic Lymphocytic Leukemia and Richter Transformation

Impact of a Validated Composite Comorbidity Score on Outcomes in Patients Treated with CAR T-Cell Therapy for Diffuse Large B Cell Lymphoma (DLBCL): A Multicenter Real-World Evidence (RWE) Study

Initial Safety Results from a Phase II Study of Acalabrutinib Plus RICE Followed By Autologous Hematopoietic Cell Transplantation and/or Acalabrutinib Maintenance Therapy for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Impact of Comorbidities on Outcomes and Toxicity in Patients Treated with CAR T-Cell Therapy for Diffuse Large B Cell Lymphoma (DLBCL): A Multicenter Rwe Study

Addressing a New Challenge in Chronic Lymphocytic Leukemia: Outcomes of Therapies after Exposure to Both a Covalent Bruton's Tyrosine Kinase Inhibitor and Venetoclax

Outcomes of Chronic Lymphocytic Leukemia and Richter Transformation Following Discontinuation of Non-Covalent Bruton's Tyrosine Kinase Inhibitors

Impact of Molecular Features of Diffuse Large B-Cell Lymphoma on Treatment Outcomes with Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy

Awareness, Knowledge, and Preferences of United States (US) Patients with Chronic Lymphocytic Leukemia (CLL) and Their Caregivers Related to Finite Duration (FD) Therapy and Minimal (Measurable) Residual Disease (MRD)

Real World Observational Study Using Clonoseq® Next Generation Sequencing in Hematologic Malignancies: The 'Watch' Registry

A Phase 2, Open-Label, Multicenter Study of Tazemetostat in Combination with Rituximab for the Treatment of Relapsed or Refractory Follicular Lymphoma

Acalabrutinib Plus RICE Followed By Autologous Hematopoietic Cell Transplantation and/or Acalabrutinib Maintenance Therapy for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only